[{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Day One Biopharmaceuticals \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Access Biotechnology"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"DAY101","moa":"pan-RAF kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"immediate-release tablet","sponsorNew":"Day One Biopharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"MEK 1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Immediate-release tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Immediate-release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Immediate-release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Sprint Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Day One Biopharmaceuticals","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MTX-13","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Day One Biopharmaceuticals","amount2":1.21,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.21,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Day One Biopharmaceuticals \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Onco360","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Onco360","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Onco360"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Tovorafenib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Fairmount","highestDevelopmentStatusID":"12","companyTruncated":"Day One Biopharmaceuticals \/ Fairmount"}]
Find Clinical Drug Pipeline Developments & Deals by Day One Biopharmaceuticals
Details :
The private placement proceeds will fund the clinical development of the late-stage product Ojemda (tovorafenib) for treating RAF-mutated Pediatric Low-Grade Glioma.
Details :
The agreement aims to commercialize Ojemda (tovorafenib), an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma, the most common form of childhood brain cancer outside the US.
Details :
Under the terms of the licensing agreement with MabCare for DAY301, a novel ADC targeting PTK-7 is being evaluated in early-stage clinical trials for the treatment of neoplasms.
Details :
Day One sold its rare pediatric disease PRV for FDA approved Ojemda (tovorafenib). It is indicated for the treatment of relapsed/refractory BRAF-mutated glioma.
Details :
Onco360 is being selected as a pharmacy partner by Day One Biopharmaceuticals for Ojemda, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
Details :
Ojemda (tovorafenib), a type II RAF inhibitor, is approved for relapsed or refractory braf-altered pediatric low-grade glioma (pLGG) in patients 6 months and older.
Details :
Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatr...
Details :
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in relapsed or progressive pediatric low-grade...
Details :
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of...
Reset All
